<h2>Organizations Voice Strong Positions on Cannabis Rescheduling</h2>
<p>The cannabis industry is buzzing this week as multiple organizations articulate their views regarding the potential rescheduling of cannabis. This follows recent comments from President Donald Trump, who indicated a decision could be made within two weeks about potentially reclassifying cannabis under the Controlled Substances Act (CSA). As the conversation unfolds, Canna Daily News remains committed to updating readers with the latest cannabis policy news.</p>
<p>Leading the charge for change is the Drug Policy Alliance, a nonprofit organization advocating for the complete descheduling of cannabis. Their petition argues that moving cannabis from Schedule I to Schedule III under the CSA will not end federal criminalization or arrest practices for cannabis-related conduct. Instead, they assert that only by descheduling cannabis entirely can true reform and justice be achieved, removing it from the federal schedule altogether.</p>
<h3>Debate Intensifies Over Federal Cannabis Policy</h3>
<p>The Drug Policy Alliance's initiative, addressed to President Trump, calls for an end to federal criminal penalties and promotes expungements for past convictions. The petition highlights views shared during Trump's 2024 presidential campaign about ceasing "needless arrests and incarceration" for cannabis possession, suggesting reforms that include using tax revenue to aid communities impacted by prohibition. It emphasizes that 88% of Americans support legal cannabis, making federal descheduling a step that truly respects public opinion.</p>
<p>Conversely, Smart Approaches to Marijuana (SAM) published a letter urging President Trump to oppose any reclassification. SAM argues for keeping cannabis as a Schedule I drug, citing concerns over its purported lack of accepted medical use and potential for abuse. SAM's President, Kevin Sabet, stresses the importance of maintaining current classifications to protect public health, particularly among children, and questions the long-term medical validation of cannabis.</p>
<h3>Industry Prepares for Potential Rescheduling Changes</h3>
<p>Meanwhile, Kim Anzarut, CEO of Allay Consulting, weighed in on the rescheduling debate. She acknowledged the President's comments as an indication that cannabis rescheduling might soon be a reality. However, Anzarut pointed out that even a shift to Schedule III would leave cannabis a controlled substance, retaining FDA and DEA oversight and affecting interstate commerce.</p>
<p>She also noted that rescheduling could provide significant tax relief for the industry by eliminating the burdensome 280E tax provision, thereby offering financial respite to licensed operators. To prepare for any changes, Anzarut advises cannabis businesses to adhere to GMP-level standards and ensure OSHA compliance, positioning themselves strategically for potential regulatory adjustments.</p>
<p>#CannabisPolicy #DeschedulingDebate #CannabisIndustryUpdate #CBDTrends #CannabisNews</p>